XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
XTL Biopharmaceuticals Ltd. has successfully concluded its Extraordinary General Meeting, with shareholders approving key proposals including the re-election of an external director and the grant of stock options to various board members and the CEO. The company, which specializes in developing treatments for autoimmune diseases and is listed on both NASDAQ and TASE, is also pursuing strategic partnerships to advance its clinical trials and seeking to expand its intellectual property portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.